HRP20030087B1 - Anti-il-12 antibodies, compositions, methods and uses - Google Patents
Anti-il-12 antibodies, compositions, methods and usesInfo
- Publication number
- HRP20030087B1 HRP20030087B1 HRP20030087AA HRP20030087A HRP20030087B1 HR P20030087 B1 HRP20030087 B1 HR P20030087B1 HR P20030087A A HRP20030087A A HR P20030087AA HR P20030087 A HRP20030087 A HR P20030087A HR P20030087 B1 HRP20030087 B1 HR P20030087B1
- Authority
- HR
- Croatia
- Prior art keywords
- antibodies
- compositions
- methods
- seq
- chain variable
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
- C07K16/244—Interleukins [IL]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P23/00—Anaesthetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P23/00—Anaesthetics
- A61P23/02—Local anaesthetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US22335800P | 2000-08-07 | 2000-08-07 | |
US23682700P | 2000-09-29 | 2000-09-29 | |
US09/920,262 US6902734B2 (en) | 2000-08-07 | 2001-08-01 | Anti-IL-12 antibodies and compositions thereof |
PCT/US2001/024720 WO2002012500A2 (en) | 2000-08-07 | 2001-08-07 | Anti-il-12 antibodies, compositions, methods and uses |
Publications (2)
Publication Number | Publication Date |
---|---|
HRP20030087A2 HRP20030087A2 (en) | 2005-10-31 |
HRP20030087B1 true HRP20030087B1 (en) | 2012-07-31 |
Family
ID=27397221
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
HRP20030087AA HRP20030087B1 (en) | 2000-08-07 | 2003-02-07 | Anti-il-12 antibodies, compositions, methods and uses |
Country Status (33)
Country | Link |
---|---|
US (15) | US6902734B2 (no) |
EP (5) | EP3178934B1 (no) |
JP (4) | JP4731094B2 (no) |
KR (1) | KR100823576B1 (no) |
CN (2) | CN101550190B (no) |
AR (1) | AR030134A1 (no) |
AT (1) | ATE431412T1 (no) |
AU (2) | AU2001281137B2 (no) |
BR (1) | BRPI0113109B8 (no) |
CA (1) | CA2418961C (no) |
CL (1) | CL2009000575A1 (no) |
CY (7) | CY1109149T1 (no) |
DE (2) | DE122009000025I1 (no) |
DK (4) | DK2305817T3 (no) |
EA (1) | EA006673B1 (no) |
ES (4) | ES2624502T3 (no) |
FR (1) | FR09C0021I2 (no) |
HK (1) | HK1135991A1 (no) |
HR (1) | HRP20030087B1 (no) |
HU (1) | HU228009B1 (no) |
IL (1) | IL154325A (no) |
LT (6) | LT2305817T (no) |
LU (3) | LU91584I2 (no) |
ME (1) | ME00326B (no) |
MX (1) | MXPA03001229A (no) |
MY (1) | MY133377A (no) |
NL (1) | NL300390I2 (no) |
NO (3) | NO330903B1 (no) |
NZ (2) | NZ535865A (no) |
PT (4) | PT3178934T (no) |
RS (1) | RS50477B (no) |
SI (4) | SI2305817T1 (no) |
WO (1) | WO2002012500A2 (no) |
Families Citing this family (95)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6277969B1 (en) * | 1991-03-18 | 2001-08-21 | New York University | Anti-TNF antibodies and peptides of human tumor necrosis factor |
US6830751B1 (en) * | 1994-03-14 | 2004-12-14 | Genetics Institute, Llc | Use of IL-12 antagonists in the treatment of rheumatoid arthritis |
US6914128B1 (en) | 1999-03-25 | 2005-07-05 | Abbott Gmbh & Co. Kg | Human antibodies that bind human IL-12 and methods for producing |
US7883704B2 (en) * | 1999-03-25 | 2011-02-08 | Abbott Gmbh & Co. Kg | Methods for inhibiting the activity of the P40 subunit of human IL-12 |
US6902734B2 (en) * | 2000-08-07 | 2005-06-07 | Centocor, Inc. | Anti-IL-12 antibodies and compositions thereof |
US20050249735A1 (en) * | 2000-08-07 | 2005-11-10 | Centocor, Inc. | Methods of treating ankylosing spondylitis using anti-TNF antibodies and peptides of human tumor necrosis factor |
AU2003218432A1 (en) * | 2002-03-26 | 2003-10-13 | Centocor, Inc. | Diabetes-related immunoglobulin derived proteins, compositions, methods and uses |
WO2003082206A2 (en) * | 2002-03-26 | 2003-10-09 | Centocor, Inc. | Multiple sclerosis-related immunoglobulin derived proteins, compositions, methods and uses |
US20040033228A1 (en) | 2002-08-16 | 2004-02-19 | Hans-Juergen Krause | Formulation of human antibodies for treating TNF-alpha associated disorders |
US7273889B2 (en) * | 2002-09-25 | 2007-09-25 | Innovative Drug Delivery Systems, Inc. | NMDA receptor antagonist formulation with reduced neurotoxicity |
EP1576011B1 (en) * | 2002-10-30 | 2009-08-12 | Genentech, Inc. | Inhibition of il-17 production |
CN102584997A (zh) * | 2002-11-08 | 2012-07-18 | 埃博灵克斯股份有限公司 | 针对肿瘤坏死因子-α的单结构域抗体及其用途 |
US20060034845A1 (en) * | 2002-11-08 | 2006-02-16 | Karen Silence | Single domain antibodies directed against tumor necrosis factor alpha and uses therefor |
US9320792B2 (en) | 2002-11-08 | 2016-04-26 | Ablynx N.V. | Pulmonary administration of immunoglobulin single variable domains and constructs thereof |
MXPA05004955A (es) * | 2002-11-08 | 2005-11-17 | Ablynx Nv | Anticuerpos de region unica dirigidos contra el factor-alfa de necrosis de tumor y usos de estos. |
US20100003253A1 (en) * | 2002-11-08 | 2010-01-07 | Ablynx N.V. | Single domain antibodies directed against epidermal growth factor receptor and uses therefor |
PT1648998E (pt) * | 2003-07-18 | 2014-11-04 | Amgen Inc | Agentes de ligação específica ao factor de crescimento do hepatócito |
GB0329146D0 (en) * | 2003-12-16 | 2004-01-21 | Glaxosmithkline Biolog Sa | Vaccine |
WO2005079837A1 (en) * | 2004-02-17 | 2005-09-01 | Schering Corporation | Methods of modulating il-23 activity; related reagents |
DK1839120T3 (da) * | 2004-12-21 | 2013-11-11 | Janssen Biotech Inc | Vektorer baseret på Anti-IL-12-antistoffer, værtsceller og fremgangsmåder til fremstilling og anvendelser |
JP2008523842A (ja) * | 2004-12-21 | 2008-07-10 | セントカー・インコーポレーテツド | 抗il−12抗体、エピトープ、組成物、方法および用途 |
AU2005330672B2 (en) * | 2005-04-18 | 2011-07-28 | Yeda Research And Development Company Limited | Stabilized anti-hepatitis B (HBV) antibody formulations |
US7700739B2 (en) * | 2005-06-30 | 2010-04-20 | Abbott Laboratories | IL-12/p40 binding proteins |
JP2007172129A (ja) * | 2005-12-20 | 2007-07-05 | Sony Corp | 不揮発性メモリアクセス制御装置および不揮発性メモリ制御システム |
WO2007137328A1 (en) * | 2006-05-26 | 2007-12-06 | Apollo Life Sciences Limited | An isolated il-12 molecule or chimeric molecules thereof |
WO2008070647A1 (en) * | 2006-12-07 | 2008-06-12 | Wyeth | Methods and compositions for assessing il-12 or the neutralization of il-12 in a sample |
SG177982A1 (en) | 2007-01-16 | 2012-02-28 | Abbott Lab | Methods for treating psoriasis |
NZ580379A (en) | 2007-03-29 | 2012-10-26 | Abbott Lab | Crystalline anti-human il-12 antibodies |
WO2009114040A2 (en) * | 2007-09-28 | 2009-09-17 | Centocor Ortho Biotech Inc. | Anti-il-12/23p40 antibodies, epitopes, formulations, compositions, methods and uses |
AU2008328781A1 (en) | 2007-11-27 | 2009-06-04 | Ablynx N.V. | Amino acid sequences directed against heterodimeric cytokines and/or their receptors and polypeptides comprising the same |
US8883146B2 (en) | 2007-11-30 | 2014-11-11 | Abbvie Inc. | Protein formulations and methods of making same |
AU2009225797A1 (en) | 2008-03-18 | 2009-09-24 | Abbvie Inc. | Methods for treating psoriasis |
BRPI0908312A2 (pt) * | 2008-05-05 | 2015-08-18 | Novimmune Sa | '' anticorpo monoclonal totalmente humano isolado, composição farmacêutica, método de alívio de um sintoma de uma indicação clínica e método de alívio de um sintoma de uma doença autoimune, distúrbio inflamatório ou distúrbio da proliferação celular'' |
KR20110093799A (ko) * | 2008-10-20 | 2011-08-18 | 아보트 러보러터리즈 | Il-12에 결합하는 항체 및 이의 정제 방법 |
TW201028433A (en) | 2008-10-20 | 2010-08-01 | Abbott Lab | Viral inactivation during purification of antibodies |
JP2012510468A (ja) * | 2008-11-28 | 2012-05-10 | アボット・ラボラトリーズ | 安定な抗体組成物およびこれを安定させるための方法 |
KR101811886B1 (ko) | 2009-05-05 | 2017-12-22 | 노비뮨 에스 에이 | 항―il―17f 항체 및 이의 사용 방법 |
RU2012114854A (ru) * | 2009-09-14 | 2013-10-27 | Эбботт Лэборетриз | Способы лечения псориаза |
EP3578205A1 (en) | 2010-08-06 | 2019-12-11 | ModernaTX, Inc. | A pharmaceutical formulation comprising engineered nucleic acids and medical use thereof |
CA3162352A1 (en) | 2010-10-01 | 2012-04-05 | Modernatx, Inc. | Modified nucleosides, nucleotides, and nucleic acids, and uses thereof |
TW201309330A (zh) * | 2011-01-28 | 2013-03-01 | Abbott Lab | 包含糖基化抗體之組合物及其用途 |
DE12722942T1 (de) | 2011-03-31 | 2021-09-30 | Modernatx, Inc. | Freisetzung und formulierung von manipulierten nukleinsäuren |
US9464124B2 (en) | 2011-09-12 | 2016-10-11 | Moderna Therapeutics, Inc. | Engineered nucleic acids and methods of use thereof |
PT3682905T (pt) | 2011-10-03 | 2022-04-07 | Modernatx Inc | Nucleósidos, nucleótidos e ácidos nucleicos modificados e respetivas utilizações |
LT2791160T (lt) | 2011-12-16 | 2022-06-10 | Modernatx, Inc. | Modifikuotos mrnr sudėtys |
WO2013087914A1 (en) | 2011-12-16 | 2013-06-20 | Synthon Biopharmaceuticals B.V. | EXPRESSION OF SECRETORY IgA ANTIBODIES IN DUCKWEED |
US9572897B2 (en) | 2012-04-02 | 2017-02-21 | Modernatx, Inc. | Modified polynucleotides for the production of cytoplasmic and cytoskeletal proteins |
CA2868996A1 (en) | 2012-04-02 | 2013-10-10 | Moderna Therapeutics, Inc. | Modified polynucleotides for the production of proteins |
US9283287B2 (en) | 2012-04-02 | 2016-03-15 | Moderna Therapeutics, Inc. | Modified polynucleotides for the production of nuclear proteins |
US9303079B2 (en) | 2012-04-02 | 2016-04-05 | Moderna Therapeutics, Inc. | Modified polynucleotides for the production of cytoplasmic and cytoskeletal proteins |
WO2013170168A1 (en) * | 2012-05-10 | 2013-11-14 | Bioatla Llc | Multi-specific monoclonal antibodies |
US9803010B2 (en) | 2012-06-27 | 2017-10-31 | Merck Sharp & Dohme Corp. | Crystalline anti-human IL-23p19 antibodies |
PL2922554T3 (pl) | 2012-11-26 | 2022-06-20 | Modernatx, Inc. | Na zmodyfikowany na końcach |
US8980864B2 (en) | 2013-03-15 | 2015-03-17 | Moderna Therapeutics, Inc. | Compositions and methods of altering cholesterol levels |
US9603775B2 (en) | 2013-04-24 | 2017-03-28 | Corning Incorporated | Delamination resistant pharmaceutical glass containers containing active pharmaceutical ingredients |
EP3052106A4 (en) | 2013-09-30 | 2017-07-19 | ModernaTX, Inc. | Polynucleotides encoding immune modulating polypeptides |
JP2016538829A (ja) | 2013-10-03 | 2016-12-15 | モデルナ セラピューティクス インコーポレイテッドModerna Therapeutics,Inc. | 低密度リポタンパク質受容体をコードするポリヌクレオチド |
MY192824A (en) | 2014-09-03 | 2022-09-12 | Boehringer Ingelheim Int | Compound targeting il-23a and tnf-alpha and uses thereof |
CN107614012A (zh) * | 2015-04-24 | 2018-01-19 | 加利福尼亚大学董事会 | 使用工程化的细胞检测、监测或治疗疾病或病况的系统及制备和使用它们的方法 |
CN109071648B (zh) * | 2015-10-23 | 2022-07-19 | 辉瑞有限公司 | 抗il-2抗体及其组合物和用途 |
CA3019164A1 (en) * | 2016-03-29 | 2017-10-05 | Janssen Biotech, Inc. | Method of treating psoriasis with increased interval dosing of anti-il12/23 antibody |
WO2018024770A1 (en) | 2016-08-03 | 2018-02-08 | Formycon Ag | Production of biosimilar ustekinumab in cho cells |
KR20190078648A (ko) * | 2016-11-16 | 2019-07-04 | 얀센 바이오테크 인코포레이티드 | 항-il23 특이적 항체로 건선을 치료하는 방법 |
WO2018106931A1 (en) | 2016-12-07 | 2018-06-14 | Progenity Inc. | Gastrointestinal tract detection methods, devices and systems |
US11597762B2 (en) | 2016-12-14 | 2023-03-07 | Biora Therapeutics, Inc. | Treatment of a disease of the gastrointestinal tract with an IL-12/IL-23 inhibitor released using an ingestible device |
KR20240038146A (ko) | 2017-01-30 | 2024-03-22 | 얀센 바이오테크 인코포레이티드 | 활성 건선성 관절염의 치료를 위한 항-tnf 항체, 조성물, 및 방법 |
KR20190115042A (ko) | 2017-02-07 | 2019-10-10 | 얀센 바이오테크 인코포레이티드 | 활성 강직성 척추염의 치료를 위한 항-tnf 항체, 조성물, 및 방법 |
WO2018224673A1 (en) | 2017-06-08 | 2018-12-13 | Zaklady Farmaceutyczne Polpharma S.A. | Improved methods of cell culture |
TW201922780A (zh) * | 2017-09-25 | 2019-06-16 | 美商健生生物科技公司 | 以抗il12/il23抗體治療狼瘡之安全且有效之方法 |
WO2019106206A1 (en) | 2017-12-01 | 2019-06-06 | Fyb 202 Project Gmbh | Stable, low viscosity, high concentration liquid formulations of an anti-il-12/23p40 antibody |
WO2019220412A2 (en) | 2018-05-18 | 2019-11-21 | Janssen Biotech, Inc. | Safe and effective method of treating lupus with anti-il12/il23 antibody |
TR201808283A2 (tr) * | 2018-06-11 | 2018-07-23 | Centurion Ilac San Ve Tic A S | Sulu farmasöti̇k etenersept bi̇leşi̇mi̇ |
WO2019246271A1 (en) | 2018-06-20 | 2019-12-26 | Progenity, Inc. | Treatment of a disease of the gastrointestinal tract with an il-12/il-23 inhibitor |
WO2019246317A1 (en) | 2018-06-20 | 2019-12-26 | Progenity, Inc. | Treatment of a disease or condition in a tissue originating from the endoderm |
SI3883606T1 (sl) | 2018-09-24 | 2023-10-30 | Janssen Biotech, Inc. | Varen in učinkovit postopek zdravljenja ulceroznega kolitisa s protitelesom proti IL12/IL23 |
WO2020106757A1 (en) | 2018-11-19 | 2020-05-28 | Progenity, Inc. | Ingestible device for delivery of therapeutic agent to the gastrointestinal tract |
US11548941B2 (en) | 2018-11-20 | 2023-01-10 | Janssen Biotech, Inc. | Safe and effective method of treating psoriasis with anti-IL-23 specific antibody |
JP2022518208A (ja) | 2019-01-15 | 2022-03-14 | ヤンセン バイオテツク,インコーポレーテツド | 若年性特発性関節炎の治療のための抗tnf抗体、組成物、及び方法 |
JP2022518250A (ja) | 2019-01-23 | 2022-03-14 | ヤンセン バイオテツク,インコーポレーテツド | 乾癬性関節炎の治療方法で使用するための抗tnf抗体組成物 |
MA55284A (fr) | 2019-03-14 | 2022-01-19 | Janssen Biotech Inc | Procédés de production de compositions d'anticorps anti-tnf |
MA55283A (fr) | 2019-03-14 | 2022-01-19 | Janssen Biotech Inc | Procédés de production de compositions d'anticorps anti-tnf |
JP2022525179A (ja) | 2019-03-14 | 2022-05-11 | ヤンセン バイオテツク,インコーポレーテツド | 抗tnf抗体組成物を産生するための産生方法 |
JP2022526493A (ja) * | 2019-03-18 | 2022-05-25 | ヤンセン バイオテツク,インコーポレーテツド | 抗il12/il23抗体を用いた小児被験者の乾癬の治療方法 |
US11780911B2 (en) | 2019-05-23 | 2023-10-10 | Janssen Biotech, Inc. | Method of treating inflammatory bowel disease with a combination therapy of antibodies to IL-23 and TNF alpha |
BR112021024425A2 (pt) | 2019-06-03 | 2022-01-18 | Janssen Biotech Inc | Composições de anticorpo anti-tnf e métodos para o tratamento de artrite psoriática |
BR112021024401A2 (pt) | 2019-06-03 | 2022-04-19 | Janssen Biotech Inc | Anticorpos anti-tnf, composições e métodos para o tratamento de espondilite anquilosante ativa |
KR20220038775A (ko) * | 2019-07-30 | 2022-03-29 | 아케소 바이오파마, 인크. | 항-인간 p40 단백질 도메인 항체 및 이의 용도 |
WO2021028752A1 (en) | 2019-08-15 | 2021-02-18 | Janssen Biotech, Inc. | Anti-tfn antibodies for treating type i diabetes |
EP3870261B1 (en) | 2019-12-13 | 2024-01-31 | Biora Therapeutics, Inc. | Ingestible device for delivery of therapeutic agent to the gastrointestinal tract |
WO2021126435A1 (en) | 2019-12-20 | 2021-06-24 | Novarock Biotherapeutics, Ltd. | Anti-interleukin-23 p19 antibodies and methods of use thereof |
US20220073603A1 (en) * | 2020-07-30 | 2022-03-10 | Janssen Biotech, Inc. | Method of Treating Psoriasis in Pediatric Subjects with Anti-IL12/IL23 Antibody |
KR20240032991A (ko) | 2021-07-09 | 2024-03-12 | 얀센 바이오테크 인코포레이티드 | 항-tnf 항체 조성물의 생성을 위한 제조 방법 |
KR20240034218A (ko) | 2021-07-09 | 2024-03-13 | 얀센 바이오테크 인코포레이티드 | 항-tnf 항체 조성물을 생산하기 위한 제조 방법 |
US20240117030A1 (en) | 2022-03-03 | 2024-04-11 | Pfizer Inc. | Multispecific antibodies and uses thereof |
US20240059799A1 (en) | 2022-05-11 | 2024-02-22 | Pfizer Inc. | Anti-tl1a antibodies and methods of use thereof |
Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1996033735A1 (en) * | 1995-04-27 | 1996-10-31 | Abgenix, Inc. | Human antibodies derived from immunized xenomice |
WO1997015327A1 (en) * | 1995-10-25 | 1997-05-01 | The Government Of The United States Of America, Represented By The Secretary, Department Of Health And Human Services | Methods of treating established colitis using antibodies against il-12 |
WO1999037682A2 (en) * | 1998-01-23 | 1999-07-29 | F.Hoffmann-La Roche Ag | Antibodies against human il-12 |
WO2000056772A1 (en) * | 1999-03-25 | 2000-09-28 | Knoll Gmbh | Human antibodies that bind human il-12 and methods for producing |
Family Cites Families (175)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US122464A (en) | 1872-01-02 | Improvement in cheese-hoops | ||
US941234A (en) | 1909-02-25 | 1909-11-23 | Frank De Clercq | Syrup-percolator. |
US3773919A (en) | 1969-10-23 | 1973-11-20 | Du Pont | Polylactide-drug mixtures |
US4309989A (en) | 1976-02-09 | 1982-01-12 | The Curators Of The University Of Missouri | Topical application of medication by ultrasound with coupling agent |
FR2374910A1 (fr) | 1976-10-23 | 1978-07-21 | Choay Sa | Preparation a base d'heparine, comprenant des liposomes, procede pour l'obtenir et medicaments contenant de telles preparations |
FR2413974A1 (fr) | 1978-01-06 | 1979-08-03 | David Bernard | Sechoir pour feuilles imprimees par serigraphie |
US4399216A (en) | 1980-02-25 | 1983-08-16 | The Trustees Of Columbia University | Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials |
US4634665A (en) | 1980-02-25 | 1987-01-06 | The Trustees Of Columbia University In The City Of New York | Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials |
US5179017A (en) | 1980-02-25 | 1993-01-12 | The Trustees Of Columbia University In The City Of New York | Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials |
US4656134A (en) | 1982-01-11 | 1987-04-07 | Board Of Trustees Of Leland Stanford Jr. University | Gene amplification in eukaryotic cells |
US5149636A (en) | 1982-03-15 | 1992-09-22 | Trustees Of Columbia University In The City Of New York | Method for introducing cloned, amplifiable genes into eucaryotic cells and for producing proteinaceous products |
US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
US5168062A (en) | 1985-01-30 | 1992-12-01 | University Of Iowa Research Foundation | Transfer vectors and microorganisms containing human cytomegalovirus immediate-early promoter-regulatory DNA sequence |
US4683202A (en) | 1985-03-28 | 1987-07-28 | Cetus Corporation | Process for amplifying nucleic acid sequences |
US4965188A (en) | 1986-08-22 | 1990-10-23 | Cetus Corporation | Process for amplifying, detecting, and/or cloning nucleic acid sequences using a thermostable enzyme |
US4683195A (en) | 1986-01-30 | 1987-07-28 | Cetus Corporation | Process for amplifying, detecting, and/or-cloning nucleic acid sequences |
US6492107B1 (en) | 1986-11-20 | 2002-12-10 | Stuart Kauffman | Process for obtaining DNA, RNA, peptides, polypeptides, or protein, by recombinant DNA technique |
GB2183661B (en) | 1985-03-30 | 1989-06-28 | Marc Ballivet | Method for obtaining dna, rna, peptides, polypeptides or proteins by means of a dna recombinant technique |
SE448277B (sv) | 1985-04-12 | 1987-02-09 | Draco Ab | Indikeringsanordning vid en doseringsanordning for lekemedel |
US4766067A (en) | 1985-05-31 | 1988-08-23 | President And Fellows Of Harvard College | Gene amplification |
GB8517895D0 (en) | 1985-07-16 | 1985-08-21 | Technology Licence Co Ltd | Monoclonal antibodies |
US4870163A (en) | 1985-08-29 | 1989-09-26 | New York Blood Center, Inc. | Preparation of pure human tumor necrosis factor and hybridomas producing monoclonal antibodies to human tumor necrosis factor |
US4676980A (en) | 1985-09-23 | 1987-06-30 | The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Target specific cross-linked heteroantibodies |
US5576195A (en) | 1985-11-01 | 1996-11-19 | Xoma Corporation | Vectors with pectate lyase signal sequence |
US5618920A (en) | 1985-11-01 | 1997-04-08 | Xoma Corporation | Modular assembly of antibody genes, antibodies prepared thereby and use |
DE3600905A1 (de) | 1986-01-15 | 1987-07-16 | Ant Nachrichtentech | Verfahren zum dekodieren von binaersignalen sowie viterbi-dekoder und anwendungen |
GB8601597D0 (en) | 1986-01-23 | 1986-02-26 | Wilson R H | Nucleotide sequences |
US4800159A (en) | 1986-02-07 | 1989-01-24 | Cetus Corporation | Process for amplifying, detecting, and/or cloning nucleic acid sequences |
SE453566B (sv) | 1986-03-07 | 1988-02-15 | Draco Ab | Anordning vid pulverinhalatorer |
US5225539A (en) | 1986-03-27 | 1993-07-06 | Medical Research Council | Recombinant altered antibodies and methods of making altered antibodies |
US4767402A (en) | 1986-07-08 | 1988-08-30 | Massachusetts Institute Of Technology | Ultrasound enhancement of transdermal drug delivery |
US4925673A (en) | 1986-08-18 | 1990-05-15 | Clinical Technologies Associates, Inc. | Delivery systems for pharmacological agents encapsulated with proteinoids |
US4889818A (en) | 1986-08-22 | 1989-12-26 | Cetus Corporation | Purified thermostable enzyme |
US4704692A (en) | 1986-09-02 | 1987-11-03 | Ladner Robert C | Computer based system and method for determining and displaying possible chemical structures for converting double- or multiple-chain polypeptides to single-chain polypeptides |
US4946778A (en) | 1987-09-21 | 1990-08-07 | Genex Corporation | Single polypeptide chain binding molecules |
US5260203A (en) | 1986-09-02 | 1993-11-09 | Enzon, Inc. | Single polypeptide chain binding molecules |
DE3631229A1 (de) | 1986-09-13 | 1988-03-24 | Basf Ag | Monoklonale antikoerper gegen humanen tumornekrosefaktor (tnf) und deren verwendung |
US4921794A (en) | 1987-01-14 | 1990-05-01 | President And Fellows Of Harvard College | T7 DNA polymerase |
US4795699A (en) | 1987-01-14 | 1989-01-03 | President And Fellows Of Harvard College | T7 DNA polymerase |
EP0832981A1 (en) | 1987-02-17 | 1998-04-01 | Pharming B.V. | DNA sequences to target proteins to the mammary gland for efficient secretion |
WO1988006630A1 (en) | 1987-03-02 | 1988-09-07 | Genex Corporation | Method for the preparation of binding molecules |
JP2647427B2 (ja) | 1987-04-24 | 1997-08-27 | 帝人株式会社 | 被検者の病態の判定のための検出方法、モノクロ−ナル抗体および検出キット |
US4873316A (en) | 1987-06-23 | 1989-10-10 | Biogen, Inc. | Isolation of exogenous recombinant proteins from the milk of transgenic mammals |
CA1341235C (en) | 1987-07-24 | 2001-05-22 | Randy R. Robinson | Modular assembly of antibody genes, antibodies prepared thereby and use |
US4939666A (en) | 1987-09-02 | 1990-07-03 | Genex Corporation | Incremental macromolecule construction methods |
EP0308936B1 (en) | 1987-09-23 | 1994-07-06 | Bristol-Myers Squibb Company | Antibody heteroconjugates for the killing of HIV-infected cells |
JP2980626B2 (ja) | 1988-01-11 | 1999-11-22 | ゾーマ・コーポレーション | ペクチン酸リアーゼのシグナル配列を含む新規プラスミドベクター |
US6010902A (en) | 1988-04-04 | 2000-01-04 | Bristol-Meyers Squibb Company | Antibody heteroconjugates and bispecific antibodies for use in regulation of lymphocyte activity |
US4956288A (en) | 1988-04-22 | 1990-09-11 | Biogen, Inc. | Method for producing cells containing stably integrated foreign DNA at a high copy number, the cells produced by this method, and the use of these cells to produce the polypeptides coded for by the foreign DNA |
US5130238A (en) | 1988-06-24 | 1992-07-14 | Cangene Corporation | Enhanced nucleic acid amplification process |
US5601819A (en) | 1988-08-11 | 1997-02-11 | The General Hospital Corporation | Bispecific antibodies for selective immune regulation and for selective immune cell binding |
US5223409A (en) | 1988-09-02 | 1993-06-29 | Protein Engineering Corp. | Directed evolution of novel binding proteins |
US5066584A (en) | 1988-09-23 | 1991-11-19 | Cetus Corporation | Methods for generating single stranded dna by the polymerase chain reaction |
US5142033A (en) | 1988-09-23 | 1992-08-25 | Hoffmann-La Roche Inc. | Structure-independent DNA amplification by the polymerase chain reaction |
US5091310A (en) | 1988-09-23 | 1992-02-25 | Cetus Corporation | Structure-independent dna amplification by the polymerase chain reaction |
US4987893A (en) | 1988-10-12 | 1991-01-29 | Rochal Industries, Inc. | Conformable bandage and coating material |
GB8823869D0 (en) | 1988-10-12 | 1988-11-16 | Medical Res Council | Production of antibodies |
CA2002607C (en) | 1988-11-10 | 2004-01-27 | Gordon G. Wong | Natural killer stimulatory factor |
US5811523A (en) | 1988-11-10 | 1998-09-22 | Trinchieri; Giorgio | Antibodies to natural killer stimulatory factor |
US5457038A (en) | 1988-11-10 | 1995-10-10 | Genetics Institute, Inc. | Natural killer stimulatory factor |
ES2052027T5 (es) | 1988-11-11 | 2005-04-16 | Medical Research Council | Clonacion de secuencias de dominio variable de inmunoglobulina. |
US5530101A (en) | 1988-12-28 | 1996-06-25 | Protein Design Labs, Inc. | Humanized immunoglobulins |
US4994370A (en) | 1989-01-03 | 1991-02-19 | The United States Of America As Represented By The Department Of Health And Human Services | DNA amplification technique |
US5116964A (en) | 1989-02-23 | 1992-05-26 | Genentech, Inc. | Hybrid immunoglobulins |
US5225538A (en) | 1989-02-23 | 1993-07-06 | Genentech, Inc. | Lymphocyte homing receptor/immunoglobulin fusion proteins |
US5266491A (en) | 1989-03-14 | 1993-11-30 | Mochida Pharmaceutical Co., Ltd. | DNA fragment and expression plasmid containing the DNA fragment |
DE3909708A1 (de) | 1989-03-23 | 1990-09-27 | Boehringer Mannheim Gmbh | Verfahren zur herstellung bispezifischer antikoerper |
AU652539B2 (en) | 1989-05-16 | 1994-09-01 | Medical Research Council | Co-expression of heteromeric receptors |
CA2016842A1 (en) | 1989-05-16 | 1990-11-16 | Richard A. Lerner | Method for tapping the immunological repertoire |
CA2016841C (en) | 1989-05-16 | 1999-09-21 | William D. Huse | A method for producing polymers having a preselected activity |
ES2096590T3 (es) | 1989-06-29 | 1997-03-16 | Medarex Inc | Reactivos biespecificos para la terapia del sida. |
CA2064915C (en) | 1989-08-07 | 2001-05-29 | Deborah A. Rathjen | Tumour necrosis factor binding ligands |
EP0494955B1 (en) | 1989-10-05 | 1998-07-15 | Optein, Inc. | Cell-free synthesis and isolation of novel genes and polypeptides |
US5859205A (en) * | 1989-12-21 | 1999-01-12 | Celltech Limited | Humanised antibodies |
US5780597A (en) * | 1989-12-22 | 1998-07-14 | Hoffmann-La Roche Inc. | Monoclonal antibodies to cytotoxic lymphocyte maturation factor |
DK0790255T3 (da) | 1989-12-22 | 2007-11-26 | Hoffmann La Roche | Monoklonale antistoffer som er rettet mod den cytotoksiske lymfocytmodningsfaktor |
US5580575A (en) | 1989-12-22 | 1996-12-03 | Imarx Pharmaceutical Corp. | Therapeutic drug delivery systems |
SG48759A1 (en) | 1990-01-12 | 2002-07-23 | Abgenix Inc | Generation of xenogenic antibodies |
TW212184B (no) | 1990-04-02 | 1993-09-01 | Takeda Pharm Industry Co Ltd | |
US5427908A (en) | 1990-05-01 | 1995-06-27 | Affymax Technologies N.V. | Recombinant library screening methods |
CA2084307A1 (en) | 1990-06-01 | 1991-12-02 | Cetus Oncology Corporation | Compositions and methods for identifying biologically active molecules |
US5723286A (en) | 1990-06-20 | 1998-03-03 | Affymax Technologies N.V. | Peptide library and screening systems |
EP0547065B1 (en) | 1990-06-29 | 2001-08-29 | Large Scale Biology Corporation | Melanin production by transformed microorganisms |
US5580734A (en) | 1990-07-13 | 1996-12-03 | Transkaryotic Therapies, Inc. | Method of producing a physical map contigous DNA sequences |
WO1992002551A1 (en) | 1990-08-02 | 1992-02-20 | B.R. Centre Limited | Methods for the production of proteins with a desired function |
US5545806A (en) | 1990-08-29 | 1996-08-13 | Genpharm International, Inc. | Ransgenic non-human animals for producing heterologous antibodies |
ES2108048T3 (es) | 1990-08-29 | 1997-12-16 | Genpharm Int | Produccion y utilizacion de animales inferiores transgenicos capaces de producir anticuerpos heterologos. |
US5770429A (en) | 1990-08-29 | 1998-06-23 | Genpharm International, Inc. | Transgenic non-human animals capable of producing heterologous antibodies |
US5789650A (en) | 1990-08-29 | 1998-08-04 | Genpharm International, Inc. | Transgenic non-human animals for producing heterologous antibodies |
US5633425A (en) | 1990-08-29 | 1997-05-27 | Genpharm International, Inc. | Transgenic non-human animals capable of producing heterologous antibodies |
US6300129B1 (en) | 1990-08-29 | 2001-10-09 | Genpharm International | Transgenic non-human animals for producing heterologous antibodies |
US5625126A (en) | 1990-08-29 | 1997-04-29 | Genpharm International, Inc. | Transgenic non-human animals for producing heterologous antibodies |
US5661016A (en) | 1990-08-29 | 1997-08-26 | Genpharm International Inc. | Transgenic non-human animals capable of producing heterologous antibodies of various isotypes |
WO1992005258A1 (en) | 1990-09-20 | 1992-04-02 | La Trobe University | Gene encoding barley enzyme |
GB9022648D0 (en) | 1990-10-18 | 1990-11-28 | Charing Cross Sunley Research | Polypeptide and its use |
AU8727291A (en) | 1990-10-29 | 1992-06-11 | Cetus Oncology Corporation | Bispecific antibodies, method of production, and uses thereof |
ES2113940T3 (es) | 1990-12-03 | 1998-05-16 | Genentech Inc | Metodo de enriquecimiento para variantes de proteinas con propiedades de union alteradas. |
US5582996A (en) | 1990-12-04 | 1996-12-10 | The Wistar Institute Of Anatomy & Biology | Bifunctional antibodies and method of preparing same |
JPH06508022A (ja) | 1991-02-21 | 1994-09-14 | ギリアド サイエンシズ,インコーポレイテッド | 生体分子に特異的なアプタマーおよび生産方法 |
US5404871A (en) | 1991-03-05 | 1995-04-11 | Aradigm | Delivery of aerosol medications for inspiration |
AU1674292A (en) | 1991-03-15 | 1992-10-21 | Synergen, Inc. | Pegylation of polypeptides |
EP0580737B1 (en) | 1991-04-10 | 2004-06-16 | The Scripps Research Institute | Heterodimeric receptor libraries using phagemids |
WO1992020373A1 (en) | 1991-05-14 | 1992-11-26 | Repligen Corporation | Heteroconjugate antibodies for treatment of hiv infection |
DE4118120A1 (de) | 1991-06-03 | 1992-12-10 | Behringwerke Ag | Tetravalente bispezifische rezeptoren, ihre herstellung und verwendung |
US5637481A (en) | 1993-02-01 | 1997-06-10 | Bristol-Myers Squibb Company | Expression vectors encoding bispecific fusion proteins and methods of producing biologically active bispecific fusion proteins in a mammalian cell |
ATE189124T1 (de) | 1991-07-02 | 2000-02-15 | Inhale Inc | Verfahren und vorrichtung zum abgeben von medikamenten in aerosolform |
US5270170A (en) | 1991-10-16 | 1993-12-14 | Affymax Technologies N.V. | Peptide library and screening method |
WO1993008829A1 (en) | 1991-11-04 | 1993-05-13 | The Regents Of The University Of California | Compositions that mediate killing of hiv-infected cells |
US5641670A (en) | 1991-11-05 | 1997-06-24 | Transkaryotic Therapies, Inc. | Protein production and protein delivery |
US5968502A (en) | 1991-11-05 | 1999-10-19 | Transkaryotic Therapies, Inc. | Protein production and protein delivery |
US5932448A (en) | 1991-11-29 | 1999-08-03 | Protein Design Labs., Inc. | Bispecific antibody heterodimers |
DE69233745D1 (de) | 1991-12-02 | 2008-10-23 | Cambridge Antibody Tech | Herstellung von Autoantikörpern auf Phagenoberflächen ausgehend von Antikörpersegmentbibliotheken |
ES2202310T3 (es) | 1991-12-13 | 2004-04-01 | Xoma Corporation | Metodos y materiales para la preparacion de dominios variables de anticuerpos modificados y sus usos terapeuticos. |
US5667988A (en) | 1992-01-27 | 1997-09-16 | The Scripps Research Institute | Methods for producing antibody libraries using universal or randomized immunoglobulin light chains |
DE4207475A1 (de) | 1992-03-10 | 1993-09-16 | Goldwell Ag | Mittel zum blondieren von menschlichen haaren und verfahren zu dessen herstellung |
US5447851B1 (en) | 1992-04-02 | 1999-07-06 | Univ Texas System Board Of | Dna encoding a chimeric polypeptide comprising the extracellular domain of tnf receptor fused to igg vectors and host cells |
AU4829593A (en) | 1992-09-23 | 1994-04-12 | Fisons Plc | Inhalation device |
WO1994008038A1 (en) | 1992-10-02 | 1994-04-14 | Trustees Of Dartmouth College | Bispecific reagents for redirected targeting of low density lipoprotein |
SK51695A3 (en) | 1992-10-19 | 1995-11-08 | Dura Pharma Inc | Dry powder medicament inhaler |
US5643252A (en) | 1992-10-28 | 1997-07-01 | Venisect, Inc. | Laser perforator |
AU5670194A (en) | 1992-11-20 | 1994-06-22 | Enzon, Inc. | Linker for linked fusion polypeptides |
US5849695A (en) | 1993-01-13 | 1998-12-15 | The Regents Of The University Of California | Parathyroid hormone analogues useful for treatment of osteoporosis and disorders of calcium meatabolism in mammals |
AU5883694A (en) | 1993-01-19 | 1994-08-15 | Glaxo Group Limited | Device |
US5300478A (en) * | 1993-01-28 | 1994-04-05 | Zeneca Limited | Substituted fused pyrazolo compounds |
EP0804561B1 (en) | 1993-02-12 | 2009-12-30 | The Board Of Trustees Of The Leland Stanford Junior University | Regulated transcription of targeted genes and other biological events |
EP0614989A1 (en) | 1993-02-17 | 1994-09-14 | MorphoSys AG | A method for in vivo selection of ligand-binding proteins |
US5770428A (en) | 1993-02-17 | 1998-06-23 | Wisconsin Alumni Research Foundation | Chimeric retrovial expression vectors and particles containing a simple retroviral long terminal repeat, BLV or HIV coding regions and cis-acting regulatory sequences, and an RNA translational enhancer with internal ribsome entry site |
JPH08509612A (ja) | 1993-04-26 | 1996-10-15 | ジェンファーム インターナショナル インコーポレイテッド | 異種抗体を産生することができるトランスジェニック非ヒト動物 |
EP0652227B1 (en) * | 1993-04-30 | 1998-02-25 | Tokyo Tanabe Company Limited | Method of purifying hydrophobic polypeptide |
DE4315127A1 (de) * | 1993-05-07 | 1994-11-10 | Behringwerke Ag | Arzneimittel enthaltend die Untereinheit p40 von Interleukin-12 |
CA2125763C (en) * | 1993-07-02 | 2007-08-28 | Maurice Kent Gately | P40 homodimer of interleukin-12 |
US5514670A (en) | 1993-08-13 | 1996-05-07 | Pharmos Corporation | Submicron emulsions for delivery of peptides |
US5625825A (en) | 1993-10-21 | 1997-04-29 | Lsi Logic Corporation | Random number generating apparatus for an interface unit of a carrier sense with multiple access and collision detect (CSMA/CD) ethernet data network |
DE4337197C1 (de) | 1993-10-30 | 1994-08-25 | Biotest Pharma Gmbh | Verfahren zur selektiven Herstellung von Hybridomazellinien, die monoklonale Antikörper mit hoher Zytotoxizität gegen humanes CD16-Antigen produzieren, sowie Herstellung bispezifischer monoklonaler Antikörper unter Verwendung derartiger monoklonaler Antikörper und des CD30-HRS-3-Antikörpers zur Therapie menschlicher Tumore |
US5814599A (en) | 1995-08-04 | 1998-09-29 | Massachusetts Insitiute Of Technology | Transdermal delivery of encapsulated drugs |
SE9304060D0 (sv) | 1993-12-06 | 1993-12-06 | Bioinvent Int Ab | Sätt att selektera specifika bakteriofager |
US5827690A (en) | 1993-12-20 | 1998-10-27 | Genzyme Transgenics Corporatiion | Transgenic production of antibodies in milk |
ES2178669T3 (es) | 1994-03-07 | 2003-01-01 | Medarex Inc | Moleculas biespecificas que tienen utilidad clinica. |
ZA95960B (en) * | 1994-03-14 | 1995-10-10 | Genetics Inst | Use of interleukin-12 antagonists in the treatment of autoimmune diseases |
WO1995029239A2 (en) | 1994-04-22 | 1995-11-02 | Corixa Corporation | Compounds and methods for the stimulation and enhancement of protective immune responses and il-12 production |
US5763733A (en) | 1994-10-13 | 1998-06-09 | Enzon, Inc. | Antigen-binding fusion proteins |
US5549551A (en) | 1994-12-22 | 1996-08-27 | Advanced Cardiovascular Systems, Inc. | Adjustable length balloon catheter |
US6086875A (en) * | 1995-01-17 | 2000-07-11 | The Brigham And Women's Hospital, Inc. | Receptor specific transepithelial transport of immunogens |
US5891680A (en) * | 1995-02-08 | 1999-04-06 | Whitehead Institute For Biomedical Research | Bioactive fusion proteins comprising the p35 and p40 subunits of IL-12 |
US5731168A (en) | 1995-03-01 | 1998-03-24 | Genentech, Inc. | Method for making heteromultimeric polypeptides |
US6037453A (en) | 1995-03-15 | 2000-03-14 | Genentech, Inc. | Immunoglobulin variants |
US5656730A (en) | 1995-04-07 | 1997-08-12 | Enzon, Inc. | Stabilized monomeric protein compositions |
AU2466895A (en) | 1995-04-28 | 1996-11-18 | Abgenix, Inc. | Human antibodies derived from immunized xenomice |
US5730723A (en) | 1995-10-10 | 1998-03-24 | Visionary Medical Products Corporation, Inc. | Gas pressured needle-less injection device and method |
GB9526100D0 (en) | 1995-12-20 | 1996-02-21 | Intersurgical Ltd | Nebulizer |
PL327616A1 (en) | 1996-01-03 | 1998-12-21 | Glaxo Group Ltd | Inhaler |
US5714352A (en) | 1996-03-20 | 1998-02-03 | Xenotech Incorporated | Directed switch-mediated DNA recombination |
DE19624387C2 (de) | 1996-06-19 | 1999-08-19 | Hatz Motoren | Kaltstartvorrichtung |
DK0826695T3 (da) | 1996-09-03 | 2002-04-15 | Gsf Forschungszentrum Umwelt | Tilintetgørelse af kontaminerende tumorceller i stamcelletransplantater med bispecifikke antistoffer |
EP2305027B1 (en) | 1996-12-03 | 2014-07-02 | Amgen Fremont Inc. | Transgenic mammals having human Ig loci including plural VH and Vkappa regions and antibodies produced therefrom |
US5879681A (en) | 1997-02-07 | 1999-03-09 | Emisphere Technolgies Inc. | Compounds and compositions for delivering active agents |
US6086876A (en) | 1997-02-07 | 2000-07-11 | The Wistar Insitute | Methods and compositions for the inhibition of interleukin-12 production |
US5921447A (en) | 1997-02-13 | 1999-07-13 | Glaxo Wellcome Inc. | Flow-through metered aerosol dispensing apparatus and method of use thereof |
US6235883B1 (en) | 1997-05-05 | 2001-05-22 | Abgenix, Inc. | Human monoclonal antibodies to epidermal growth factor receptor |
IL120943A (en) | 1997-05-29 | 2004-03-28 | Univ Ben Gurion | A system for administering drugs through the skin |
US6060284A (en) * | 1997-07-25 | 2000-05-09 | Schering Corporation | DNA encoding interleukin-B30 |
ATE305506T1 (de) | 1998-12-09 | 2005-10-15 | Protein Design Labs Inc | Verwendung von il-12 antikörpern zur behandlung von psoriasis |
US6914128B1 (en) * | 1999-03-25 | 2005-07-05 | Abbott Gmbh & Co. Kg | Human antibodies that bind human IL-12 and methods for producing |
AU7127600A (en) | 1999-09-17 | 2001-04-17 | Basf Aktiengesellschaft | Methods and compositions for modulating responsiveness to corticosteroids |
US6902734B2 (en) * | 2000-08-07 | 2005-06-07 | Centocor, Inc. | Anti-IL-12 antibodies and compositions thereof |
EP1506302A4 (en) | 2002-05-23 | 2006-02-08 | Cognis Ip Man Gmbh | CANDIDA TROPICALIS BLOCKED BY OXIDATION BETA NON REVERSIBLE |
DE102007030072A1 (de) | 2007-06-29 | 2009-01-02 | BSH Bosch und Siemens Hausgeräte GmbH | Elektrischen Antriebseinrichtung für ein Wasserführendes Haushaltsgerät |
JP5470817B2 (ja) | 2008-03-10 | 2014-04-16 | 日産自動車株式会社 | 電池用電極およびこれを用いた電池、並びにその製造方法 |
JP5155355B2 (ja) | 2010-04-07 | 2013-03-06 | レノボ・シンガポール・プライベート・リミテッド | 無線基地局の自律的な負荷調整が可能な無線端末装置 |
US9619256B1 (en) | 2012-06-27 | 2017-04-11 | EMC IP Holding Company LLC | Multi site and multi tenancy |
JP6136279B2 (ja) | 2013-01-15 | 2017-05-31 | 株式会社ジェイテクト | 転がり軸受装置 |
TWI503850B (zh) | 2013-03-22 | 2015-10-11 | Polytronics Technology Corp | 過電流保護元件 |
TWI510996B (zh) | 2013-10-03 | 2015-12-01 | Acer Inc | 控制觸控面板的方法以及使用該方法的可攜式電腦 |
US9205258B2 (en) | 2013-11-04 | 2015-12-08 | ElectroCore, LLC | Nerve stimulator system |
US9816280B1 (en) | 2016-11-02 | 2017-11-14 | Matthew Reitnauer | Portable floor |
-
2001
- 2001-08-01 US US09/920,262 patent/US6902734B2/en not_active Expired - Lifetime
- 2001-08-07 SI SI200131066T patent/SI2305817T1/en unknown
- 2001-08-07 PT PT171533367T patent/PT3178934T/pt unknown
- 2001-08-07 DK DK10184116.1T patent/DK2305817T3/en active
- 2001-08-07 ES ES09006396.7T patent/ES2624502T3/es not_active Expired - Lifetime
- 2001-08-07 SI SI200131060A patent/SI2090657T1/sl unknown
- 2001-08-07 PT PT101841161T patent/PT2305817T/pt unknown
- 2001-08-07 AR ARP010103780A patent/AR030134A1/es active IP Right Grant
- 2001-08-07 ES ES17153336T patent/ES2747573T3/es not_active Expired - Lifetime
- 2001-08-07 ES ES01959598T patent/ES2323760T3/es not_active Expired - Lifetime
- 2001-08-07 DE DE122009000025C patent/DE122009000025I1/de active Pending
- 2001-08-07 DK DK01959598T patent/DK1309692T3/da active
- 2001-08-07 AT AT01959598T patent/ATE431412T1/de active
- 2001-08-07 EP EP17153336.7A patent/EP3178934B1/en not_active Expired - Lifetime
- 2001-08-07 EP EP01959598A patent/EP1309692B1/en not_active Expired - Lifetime
- 2001-08-07 SI SI200130913T patent/SI1309692T1/sl unknown
- 2001-08-07 WO PCT/US2001/024720 patent/WO2002012500A2/en active IP Right Grant
- 2001-08-07 EA EA200300137A patent/EA006673B1/ru not_active IP Right Cessation
- 2001-08-07 LT LTEP10184116.1T patent/LT2305817T/lt unknown
- 2001-08-07 DK DK17153336.7T patent/DK3178934T3/da active
- 2001-08-07 LT LTEP17153336.7T patent/LT3178934T/lt unknown
- 2001-08-07 IL IL154325A patent/IL154325A/en active Protection Beyond IP Right Term
- 2001-08-07 AU AU2001281137A patent/AU2001281137B2/en active Active
- 2001-08-07 ME MEP-2008-444A patent/ME00326B/me unknown
- 2001-08-07 MY MYPI20013706 patent/MY133377A/en unknown
- 2001-08-07 EP EP19179253.0A patent/EP3597752A1/en not_active Withdrawn
- 2001-08-07 SI SI200131070T patent/SI3178934T1/sl unknown
- 2001-08-07 CA CA002418961A patent/CA2418961C/en not_active Expired - Lifetime
- 2001-08-07 NZ NZ535865A patent/NZ535865A/en not_active IP Right Cessation
- 2001-08-07 BR BRPI0113109A patent/BRPI0113109B8/pt active IP Right Grant
- 2001-08-07 NZ NZ524145A patent/NZ524145A/en not_active IP Right Cessation
- 2001-08-07 PT PT01959598T patent/PT1309692E/pt unknown
- 2001-08-07 PT PT90063967T patent/PT2090657T/pt unknown
- 2001-08-07 JP JP2002517788A patent/JP4731094B2/ja not_active Expired - Lifetime
- 2001-08-07 AU AU8113701A patent/AU8113701A/xx active Pending
- 2001-08-07 LT LTEP09006396.7T patent/LT2090657T/lt unknown
- 2001-08-07 RS YUP-93/03A patent/RS50477B/sr unknown
- 2001-08-07 ES ES10184116.1T patent/ES2647220T3/es not_active Expired - Lifetime
- 2001-08-07 CN CN200810100025.3A patent/CN101550190B/zh not_active Expired - Lifetime
- 2001-08-07 HU HU0302378A patent/HU228009B1/hu active Protection Beyond IP Right Term
- 2001-08-07 DK DK09006396.7T patent/DK2090657T3/en active
- 2001-08-07 CN CNA018169619A patent/CN1468309A/zh active Pending
- 2001-08-07 EP EP10184116.1A patent/EP2305817B1/en not_active Expired - Lifetime
- 2001-08-07 KR KR1020037001843A patent/KR100823576B1/ko active Protection Beyond IP Right Term
- 2001-08-07 DE DE60138711T patent/DE60138711D1/de not_active Expired - Lifetime
- 2001-08-07 MX MXPA03001229A patent/MXPA03001229A/es active IP Right Grant
- 2001-08-07 EP EP09006396.7A patent/EP2090657B1/en not_active Expired - Lifetime
-
2003
- 2003-02-07 HR HRP20030087AA patent/HRP20030087B1/xx not_active IP Right Cessation
- 2003-02-07 NO NO20030614A patent/NO330903B1/no not_active IP Right Cessation
-
2004
- 2004-08-06 US US10/912,994 patent/US20050002937A1/en not_active Abandoned
- 2004-10-28 US US10/975,740 patent/US7063964B2/en not_active Expired - Lifetime
- 2004-10-28 US US10/975,708 patent/US7166285B2/en not_active Expired - Lifetime
- 2004-10-28 US US10/975,883 patent/US7279157B2/en not_active Expired - Lifetime
-
2007
- 2007-01-29 US US11/668,256 patent/US7560247B2/en not_active Expired - Lifetime
-
2009
- 2009-03-11 CL CL2009000575A patent/CL2009000575A1/es unknown
- 2009-05-13 FR FR09C0021C patent/FR09C0021I2/fr active Active
- 2009-05-13 NL NL300390C patent/NL300390I2/nl unknown
- 2009-05-15 LT LTPA2009002C patent/LTC1309692I2/lt unknown
- 2009-06-09 CY CY20091100601T patent/CY1109149T1/el unknown
- 2009-06-12 CY CY2009007C patent/CY2009007I2/el unknown
- 2009-07-09 US US12/500,120 patent/US7887807B2/en not_active Expired - Fee Related
- 2009-07-10 LU LU91584C patent/LU91584I2/fr unknown
-
2010
- 2010-01-05 HK HK10100042.6A patent/HK1135991A1/zh not_active IP Right Cessation
- 2010-12-17 US US12/971,626 patent/US8084233B2/en not_active Expired - Fee Related
-
2011
- 2011-03-10 JP JP2011052971A patent/JP2011173884A/ja not_active Withdrawn
- 2011-10-04 NO NO2011023C patent/NO2011023I1/no not_active IP Right Cessation
- 2011-10-26 JP JP2011235204A patent/JP2012025779A/ja active Pending
- 2011-11-18 US US13/299,874 patent/US8329171B2/en not_active Expired - Lifetime
-
2012
- 2012-11-07 US US13/670,918 patent/US8703141B2/en not_active Expired - Fee Related
-
2014
- 2014-02-26 US US14/190,893 patent/US9409984B2/en not_active Expired - Lifetime
- 2014-09-22 JP JP2014192690A patent/JP6076303B2/ja not_active Expired - Lifetime
-
2016
- 2016-06-30 US US15/198,678 patent/US9676848B2/en not_active Expired - Lifetime
-
2017
- 2017-05-01 US US15/583,487 patent/US10259867B2/en not_active Expired - Fee Related
- 2017-05-18 CY CY20171100525T patent/CY1118901T1/el unknown
- 2017-12-05 CY CY20171101269T patent/CY1119650T1/el unknown
-
2018
- 2018-03-19 CY CY2018010C patent/CY2018010I1/el unknown
- 2018-03-20 LU LU00066C patent/LUC00066I2/fr unknown
- 2018-03-20 LT LTPA2018007C patent/LTC2305817I2/lt unknown
-
2019
- 2019-02-25 US US16/284,316 patent/US10519231B2/en not_active Expired - Fee Related
- 2019-10-02 CY CY20191101021T patent/CY1122505T1/el unknown
- 2019-11-07 US US16/677,120 patent/US11078267B2/en not_active Expired - Lifetime
-
2020
- 2020-01-10 LU LU00145C patent/LUC00145I2/fr unknown
- 2020-01-13 LT LTPA2020001C patent/LTPA2020001I1/lt unknown
- 2020-01-16 CY CY2020003C patent/CY2020003I1/el unknown
- 2020-03-11 NO NO2020005C patent/NO2020005I1/no unknown
Patent Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1996033735A1 (en) * | 1995-04-27 | 1996-10-31 | Abgenix, Inc. | Human antibodies derived from immunized xenomice |
WO1997015327A1 (en) * | 1995-10-25 | 1997-05-01 | The Government Of The United States Of America, Represented By The Secretary, Department Of Health And Human Services | Methods of treating established colitis using antibodies against il-12 |
WO1999037682A2 (en) * | 1998-01-23 | 1999-07-29 | F.Hoffmann-La Roche Ag | Antibodies against human il-12 |
WO2000056772A1 (en) * | 1999-03-25 | 2000-09-28 | Knoll Gmbh | Human antibodies that bind human il-12 and methods for producing |
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
HRP20030087B1 (en) | Anti-il-12 antibodies, compositions, methods and uses | |
RS51197B (sr) | Anti-dual integrinska antitela, sastavi, metode i njihove upotrebe | |
CY2019029I2 (el) | Anti-tnf αντισωματα, συνθεσεις, μεθοδοi και χρησεις | |
HK1038069A1 (en) | Immunoassay for c.reactive protein | |
RS51829B (sr) | Ljudska antitela specifična za interleukin 15 (il-15) | |
RS54133B1 (en) | ANTI-IL-6 ANTIBODIES, PREPARATIONS, PREPARATION AND USE PROCEDURES | |
DK1414858T3 (da) | Kamelid-enkeltkæde-VHH-antistoffer, fremgangsmåde til fremstilling heraf i et pattedyr samt anvendelser heraf | |
RS52036B (en) | ANGIOPOETIN-2 ANTIBODIES AND ITS USES | |
DK2230299T3 (da) | Hidtil ukendt cytokin ZCYTOR17-ligand | |
WO2003060080A3 (en) | Canine immunoglobulin variable domains, caninized antibodies, and methods for making and using them | |
RS52769B (sr) | Kompozicije i postupci za povećanje mineralizacije kostiju | |
GB0129105D0 (en) | Expression control using variable intergenic sequences | |
NZ595450A (en) | Antibodies to M-CSF | |
IN2009KN02655A (no) | ||
ATE447587T1 (de) | Anti-il-20-antikörper und bindungspartner und verfahren zur anwendung bei entzündungen | |
TR200202799T3 (tr) | AB peptidini sekanslayan insanlaştırılmış antikorlar | |
DK1268766T3 (da) | Forbedringer af ribosom-display | |
DE69430523T2 (de) | Herstellung von photoprotein konjugaten und verfahren zu ihrer verwendung | |
RS51406B (sr) | Monoklonska antitela na humani ldl receptor, njihova produkcija i korišćenje | |
SE0002835D0 (sv) | Method and kit for production of monoclonal antibodies | |
CA2441187A1 (en) | Acetyllysine-recognizing monoclonal antibody and process for producing the same | |
DK0476059T3 (da) | Fremgangsmåder til forøgelse af modificeringshastigheden for metastabile bindinger | |
TNSN96129A1 (fr) | Ciment a resistance initiale ultra-elevee et a durcissement tres rapide. | |
MY155265A (en) | Anti-dual integrin antibodies, compositions, methods and uses | |
ATA19382001A (de) | Automatischer verbindungsaufbau zwischen sich bewegenden gegenstellen durch stufenweise korrelation von zuständigkeitsbereichen mit ortungsdaten |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A1OB | Publication of a patent application | ||
ARAI | Request for the grant of a patent on the basis of the submitted results of a substantive examination of a patent application | ||
AIPI | Request for the grant of a patent on the basis of a substantive examination of a patent application | ||
NPPZ | Continued processing | ||
NPPU | Continued processing adopted | ||
B1PR | Patent granted | ||
PNAN | Change of the applicant name, address/residence |
Owner name: JANSSEN BIOTECH, INC., US Owner name: ORTHO BIOTECH, INC., US |
|
ODRP | Renewal fee for the maintenance of a patent |
Payment date: 20190715 Year of fee payment: 19 |
|
ODRP | Renewal fee for the maintenance of a patent |
Payment date: 20200727 Year of fee payment: 20 |
|
PB20 | Patent expired after termination of 20 years |
Effective date: 20210807 |